WO2016118951A3 - Heterocyclic itk inhibitors for treating inflammation and cancer - Google Patents

Heterocyclic itk inhibitors for treating inflammation and cancer Download PDF

Info

Publication number
WO2016118951A3
WO2016118951A3 PCT/US2016/014729 US2016014729W WO2016118951A3 WO 2016118951 A3 WO2016118951 A3 WO 2016118951A3 US 2016014729 W US2016014729 W US 2016014729W WO 2016118951 A3 WO2016118951 A3 WO 2016118951A3
Authority
WO
WIPO (PCT)
Prior art keywords
heterocyclic
cancer
treating inflammation
itk inhibitors
itk
Prior art date
Application number
PCT/US2016/014729
Other languages
French (fr)
Other versions
WO2016118951A2 (en
Inventor
Eric Jon Jacobsen
James Robert BLINN
John Robert Springer
Susan K. HOCKERMAN
Original Assignee
Confluence Life Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Confluence Life Sciences, Inc. filed Critical Confluence Life Sciences, Inc.
Priority to EP16740898.8A priority Critical patent/EP3247353A4/en
Priority to CA2973597A priority patent/CA2973597A1/en
Priority to MX2017009571A priority patent/MX2017009571A/en
Priority to AU2016209046A priority patent/AU2016209046A1/en
Priority to JP2017535666A priority patent/JP2018502853A/en
Priority to CN201680006285.7A priority patent/CN107278202A/en
Priority to KR1020177020601A priority patent/KR20170103838A/en
Publication of WO2016118951A2 publication Critical patent/WO2016118951A2/en
Publication of WO2016118951A3 publication Critical patent/WO2016118951A3/en
Priority to HK18105512.8A priority patent/HK1245677A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Disclosed herein are heterocyclic compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein R1, R2, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
PCT/US2016/014729 2015-01-23 2016-01-25 Heterocyclic itk inhibitors for treating inflammation and cancer WO2016118951A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP16740898.8A EP3247353A4 (en) 2015-01-23 2016-01-25 Heterocyclic itk inhibitors for treating inflammation and cancer
CA2973597A CA2973597A1 (en) 2015-01-23 2016-01-25 Heterocyclic itk inhibitors for treating inflammation and cancer
MX2017009571A MX2017009571A (en) 2015-01-23 2016-01-25 Heterocyclic itk inhibitors for treating inflammation and cancer.
AU2016209046A AU2016209046A1 (en) 2015-01-23 2016-01-25 Heterocyclic ITK inhibitors for treating inflammation and cancer
JP2017535666A JP2018502853A (en) 2015-01-23 2016-01-25 Heterocyclic ITK inhibitors for treating inflammation and cancer
CN201680006285.7A CN107278202A (en) 2015-01-23 2016-01-25 Heterocycle ITK inhibitor for treating inflammation and cancer
KR1020177020601A KR20170103838A (en) 2015-01-23 2016-01-25 Heterocyclic itk inhibitors for treating inflammation and cancer
HK18105512.8A HK1245677A1 (en) 2015-01-23 2018-04-27 Heterocyclic itk inhibitors for treating inflammation and cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562107078P 2015-01-23 2015-01-23
US62/107,078 2015-01-23

Publications (2)

Publication Number Publication Date
WO2016118951A2 WO2016118951A2 (en) 2016-07-28
WO2016118951A3 true WO2016118951A3 (en) 2016-11-10

Family

ID=56417930

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/014729 WO2016118951A2 (en) 2015-01-23 2016-01-25 Heterocyclic itk inhibitors for treating inflammation and cancer

Country Status (10)

Country Link
US (3) US9695200B2 (en)
EP (1) EP3247353A4 (en)
JP (1) JP2018502853A (en)
KR (1) KR20170103838A (en)
CN (1) CN107278202A (en)
AU (1) AU2016209046A1 (en)
CA (1) CA2973597A1 (en)
HK (1) HK1245677A1 (en)
MX (1) MX2017009571A (en)
WO (1) WO2016118951A2 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
TWI659021B (en) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Inhibitors of kras g12c
JO3556B1 (en) 2014-09-18 2020-07-05 Araxes Pharma Llc Combination therapies for treatment of cancer
EP3218376B1 (en) 2014-11-10 2019-12-25 Genentech, Inc. Bromodomain inhibitors and uses thereof
MA40940A (en) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS
MA40943A (en) * 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS
WO2016118951A2 (en) 2015-01-23 2016-07-28 Confluence Life Sciences, Inc. Heterocyclic itk inhibitors for treating inflammation and cancer
WO2016123391A1 (en) 2015-01-29 2016-08-04 Genentech, Inc. Therapeutic compounds and uses thereof
ES2898765T3 (en) 2015-04-10 2022-03-08 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EP3283462B1 (en) 2015-04-15 2020-12-02 Araxes Pharma LLC Fused-tricyclic inhibitors of kras and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058805A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058768A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3162875B1 (en) * 2015-10-30 2018-05-23 Merck Patent GmbH Polymerisable compounds and the use thereof in liquid-crystal displays
EA038635B9 (en) 2015-11-16 2021-10-26 Араксис Фарма Ллк 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
EP3170822A1 (en) * 2015-11-18 2017-05-24 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
TWI740873B (en) * 2015-12-24 2021-10-01 日商協和麒麟股份有限公司 α, β unsaturated amide compounds
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
CN110036010A (en) 2016-09-29 2019-07-19 亚瑞克西斯制药公司 The inhibitor of KRAS G12C mutain
EP3523289A1 (en) 2016-10-07 2019-08-14 Araxes Pharma LLC Heterocyclic compounds as inhibitors of ras and methods of use thereof
WO2018140648A1 (en) * 2017-01-25 2018-08-02 Eric Jon Jacobsen Pyrrolopyrimidine itk inhibitors for treating inflammation and cancer
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018140600A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused hetero-hetero bicyclic compounds and methods of use thereof
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US10604171B2 (en) 2017-01-26 2020-03-31 Mando Corporation Steering column
MX2019009200A (en) * 2017-02-03 2019-10-21 Univ California Compositions and methods for inhibiting reticulon 4.
JP2020512981A (en) * 2017-03-31 2020-04-30 カーザ グローバル，リミティド ライアビリティ カンパニー Compositions and methods containing substituted 2-aminoimidazoles
CN110832070A (en) 2017-05-10 2020-02-21 艾欧凡斯生物治疗公司 Expansion of liquid tumor-derived tumor infiltrating lymphocytes and therapeutic uses thereof
EP3630746A1 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Compounds and methods of use thereof for treatment of cancer
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
TW201900633A (en) 2017-05-25 2019-01-01 美商亞瑞克西斯製藥公司 KRAS covalent inhibitor
WO2018235926A1 (en) * 2017-06-23 2018-12-27 協和発酵キリン株式会社 α, β-UNSATURATED AMIDE COMPOUND
JP2021503885A (en) 2017-11-22 2021-02-15 アイオバンス バイオセラピューティクス，インコーポレイテッド Expanded culture of peripheral blood lymphocytes (PBL) from peripheral blood
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
CA3109192A1 (en) * 2018-08-10 2020-02-13 Aclaris Therapeutics, Inc. Pyrrolopyrimidine itk inhibitors
EP3613738A1 (en) * 2018-08-23 2020-02-26 Lead Discovery Center GmbH 4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer
WO2020102686A1 (en) * 2018-11-16 2020-05-22 California Institute Of Technology Erk inhibitors and uses thereof
CN111518094B (en) * 2019-02-01 2021-05-25 四川大学华西医院 Anti-influenza small molecule compound and preparation method and application thereof
MX2021010288A (en) 2019-03-01 2021-09-23 Iovance Biotherapeutics Inc Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof.
US11171132B2 (en) * 2019-10-03 2021-11-09 Globalfoundries U.S. Inc. Bi-directional breakdown silicon controlled rectifiers
EP4212531A1 (en) 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707989A (en) * 1994-09-07 1998-01-13 Dr. Karl Thomae Gmbh Pyrimido 5,4-D!pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
US20140315909A1 (en) * 2013-04-18 2014-10-23 Arrien Pharmaceuticals Llc 3,5-(Un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H- pyrrolo[2,3-b]pyrazine dual ITK and JAK3 Kinase Inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100229343B1 (en) 1993-11-30 1999-11-01 윌리암스 로저 에이 Substituted pyrazolyl benzene sulfoneamides for the treatment of inflammation
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
US6610692B1 (en) 1998-10-30 2003-08-26 Merck & Co., Inc. Thrombin inhibitors
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
BR0116539A (en) 2000-12-28 2003-09-23 Shionogi & Co Pyridone derivatives having a cannabinoid receptor 2 binding activity
DE10140108A1 (en) 2001-08-16 2003-03-06 Bayer Cropscience Ag Fungicidal active ingredient combinations
WO2004078756A2 (en) * 2003-03-06 2004-09-16 Eisai Co., Ltd. Jnk inhibitors
US20050239806A1 (en) 2004-01-13 2005-10-27 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
MX2007001127A (en) * 2004-07-27 2007-07-11 Sgx Pharmaceuticals Inc Pyrrolo-pyridine kinase modulators.
US7709645B2 (en) * 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
BRPI0517652A (en) 2004-11-08 2008-10-14 Baxter Healthcare Sa nanoparticulate pharmaceutical compositions of tubulin inhibitors, methods for their preparation and their uses
JP4954086B2 (en) * 2004-12-08 2012-06-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 1H-pyrrolo [2,3-B] pyridine
US7786130B2 (en) 2005-08-29 2010-08-31 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
DE102006012617A1 (en) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4- (pyrrolopyridinyl) -pyrimidinyl-2-amine derivatives
EP2114898A2 (en) 2007-02-16 2009-11-11 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
CA2683398A1 (en) * 2007-04-10 2008-10-16 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
EP2070928A1 (en) 2007-12-12 2009-06-17 NERVIANO MEDICAL SCIENCES S.r.l. 7-azaindol-3-ylacrylamides active as kinase inhibitors
CN101952294B (en) 2008-02-25 2014-11-26 霍夫曼-拉罗奇有限公司 Pyrrolopyrazine kinase inhibitors
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
BRPI0914891A2 (en) 2008-06-20 2015-11-24 Metabolex Inc aril gpr119 agonists and uses thereof
DE102008031517A1 (en) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amine derivatives
US20110201599A1 (en) 2008-07-03 2011-08-18 Exelixis, Inc. CDK Modulators
ATE542813T1 (en) 2008-08-06 2012-02-15 Pfizer 6-SUBSTITUTED 2-HETEROCYCLYLAMINOPYRAZINE COMPOUNDS AS CHK-1 INHIBITORS
DE102008052943A1 (en) 2008-10-23 2010-04-29 Merck Patent Gmbh azaindole derivatives
JP5571168B2 (en) 2009-04-27 2014-08-13 カシナ ライラ イノバ ファーマシューティカルズ プライベート リミテッド Anti-cancer drugs and uses related to malignant melanoma and other cancers
ES2659725T3 (en) 2009-05-05 2018-03-19 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and disorder treatment procedure
EP2266562A1 (en) 2009-06-23 2010-12-29 Centre National de la Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
AU2010321883A1 (en) 2009-11-18 2012-05-31 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
TWI619713B (en) 2010-04-21 2018-04-01 普雷辛肯公司 Compounds and methods for kinase modulation, and indications therefor
MX2013000103A (en) * 2010-06-23 2013-06-13 Vertex Pharma Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase.
ES2561277T3 (en) 2010-09-01 2016-02-25 Gilead Connecticut, Inc. Pyridinones / pyrazinones, procedure of preparation and procedure of use of the same
DE102010049877A1 (en) 2010-11-01 2012-05-03 Merck Patent Gmbh 7 - ((1,2,3) triazol-4-yl) -pyrrolo (2,3) pyrazine derivatives
KR101236731B1 (en) * 2010-11-02 2013-02-25 한국과학기술원 Azaindole compounds, PI3K inhibitoring composition and composition used in diseases linked to PI3K comprising the same
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
WO2012158785A1 (en) * 2011-05-17 2012-11-22 Principia Biopharma Inc. Azaindole derivatives as tyrosine kinase inhibitors
WO2013153539A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. Tricyclic compounds as tec kinase inhibitors
US9505765B2 (en) 2012-07-26 2016-11-29 Confluence Life Sciences Inc. 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment
JP2016500076A (en) * 2012-11-20 2016-01-07 プリンシピア バイオファーマ インコーポレイテッド Azaindole derivatives as JAK3 inhibitors
GB2515785A (en) * 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
MA39092B1 (en) * 2013-12-05 2018-09-28 Pfizer Pyrrolo [2,3-d] pyrimidinyl, pyrrolo [2,3-b] pyrazinyl and pyrollo [2,3-d] pyridinyl acrylamides
WO2015112847A1 (en) 2014-01-24 2015-07-30 Confluence Life Sciences, Inc. Arylpyridinone itk inhibitors for treating inflammation and cancer
US9145393B2 (en) 2014-01-24 2015-09-29 Confluence Life Sciences, Inc. Arylpyridinone ITK inhibitors for treating inflammation and cancer
AU2015209189A1 (en) 2014-01-24 2016-07-28 Confluence Life Sciences, Inc. Substituted pyroolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases
CN105777756B (en) * 2014-07-02 2019-03-01 广东东阳光药业有限公司 Heteroaryl compound and its application in drug
WO2016118951A2 (en) 2015-01-23 2016-07-28 Confluence Life Sciences, Inc. Heterocyclic itk inhibitors for treating inflammation and cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707989A (en) * 1994-09-07 1998-01-13 Dr. Karl Thomae Gmbh Pyrimido 5,4-D!pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
US20140315909A1 (en) * 2013-04-18 2014-10-23 Arrien Pharmaceuticals Llc 3,5-(Un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H- pyrrolo[2,3-b]pyrazine dual ITK and JAK3 Kinase Inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3247353A4 *

Also Published As

Publication number Publication date
EP3247353A4 (en) 2018-07-04
HK1245677A1 (en) 2018-08-31
US20190106439A1 (en) 2019-04-11
CN107278202A (en) 2017-10-20
US20160213653A1 (en) 2016-07-28
KR20170103838A (en) 2017-09-13
US9695200B2 (en) 2017-07-04
WO2016118951A2 (en) 2016-07-28
CA2973597A1 (en) 2016-07-28
US20170260211A1 (en) 2017-09-14
AU2016209046A1 (en) 2017-07-20
MX2017009571A (en) 2018-09-27
JP2018502853A (en) 2018-02-01
US10150783B2 (en) 2018-12-11
EP3247353A2 (en) 2017-11-29

Similar Documents

Publication Publication Date Title
WO2016118951A3 (en) Heterocyclic itk inhibitors for treating inflammation and cancer
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX2022005290A (en) Heterocyclic compounds as immunomodulators.
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
PH12018500121A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
ZA201904522B (en) Heterocyclic inhibitors of mct4
PH12016501750A1 (en) Human plasma kallikrein inhibitors
WO2015168466A8 (en) Inhibitors of lysine specific demethylase-1
PH12021550187A1 (en) Pyrrolopyrimidine itk inhibitors
MX2017013797A (en) Janus kinase inhibitor.
MX2017004618A (en) Heparan sulfate biosynthesis inhibitors for the treatment of diseases.
WO2016004404A3 (en) Gls1 inhibitors for treating disease
WO2016004413A3 (en) Gls1 inhibitors for treating disease
MX2022007436A (en) Autotaxin inhibitors and uses thereof.
MX2016014436A (en) Heterocyclyl-butanamide derivatives.
MX2021010297A (en) Human plasma kallikrein inhibitors.
MX2016008042A (en) Imidazopyrazinone derivatives.
MX2016001536A (en) Piperidine urea derivatives.
MX2018005515A (en) 1,4-dicarbonyl-piperidyl derivatives.
EP3327001A4 (en) Novel compound having blt inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
WO2014138616A3 (en) Pyrazole compounds and methods of use thereof
WO2016144704A3 (en) Heterocyclic autotaxin inhibitor compounds
WO2016112304A8 (en) Furoquinolinediones as inhibitors of tdp2
MX2019014773A (en) Ccl2 inhibitors.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16740898

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2017535666

Country of ref document: JP

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2016740898

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2973597

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2016209046

Country of ref document: AU

Date of ref document: 20160125

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20177020601

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/009571

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE